Tips from Other Journals

Reviewing Clinical Features of Löfgren's Syndrome



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Feb 15;61(4):1133-1134.

Löfgren's syndrome, a benign form of sarcoidosis, is an association of erythema nodosum and bilateral hilar lymphadenopathy. Mañá and colleagues reviewed clinical features and outcomes in patients with Löfgren's syndrome.

The authors prospectively followed patients with Löfgren's syndrome who were diagnosed over a 22-year period. Löfgren's syndrome was defined as erythema nodosum, periarticular ankle inflammation, or both, plus bilateral hilar or right paratracheal adenopathy. The diagnosis of sarcoidosis was made according to accepted criteria, and sarcoid activity was similarly determined (see accompanying table). Patients without a biopsy-confirmed case of sarcoid were included if their tuberculin test was negative and other diseases were ruled out.

Criteria for Sarcoidosis Activity*

Clinical features consistent with sarcoidosis†

Abnormalities on chest radiograph (mediastinal lymphadenopathy or pulmonary infiltration)

Decreased forced vital capacity or carbon monoxide diffusing capacity (< 80% predicted)

Increased serum calcium level (> 10.5 mg per dL [2.6 mmol per L])

Increased serum angiotensin-converting enzyme level

Increased gallium-67 scan (≥liver uptake)

Alveolitis (> 14% of lymphocytes) in bronchoalveolar lavage fluid

Positive biopsy or Kveim test


*—Presence of, or changes in, any of the listed criteria constitute evidence of disease activity.

—Skin lesions (erythema nodosum or granulomas), polyarthralgia/arthritis, respiratory symptoms (cough, dyspnea), fever, uveitis, hepatosplenomegaly, parotid enlargement, upper respiratory tract involvement, neurologic symptoms.

Reprinted with permission from Mañá J, et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med 1999;107:241.

Criteria for Sarcoidosis Activity*

View Table

Criteria for Sarcoidosis Activity*

Clinical features consistent with sarcoidosis†

Abnormalities on chest radiograph (mediastinal lymphadenopathy or pulmonary infiltration)

Decreased forced vital capacity or carbon monoxide diffusing capacity (< 80% predicted)

Increased serum calcium level (> 10.5 mg per dL [2.6 mmol per L])

Increased serum angiotensin-converting enzyme level

Increased gallium-67 scan (≥liver uptake)

Alveolitis (> 14% of lymphocytes) in bronchoalveolar lavage fluid

Positive biopsy or Kveim test


*—Presence of, or changes in, any of the listed criteria constitute evidence of disease activity.

—Skin lesions (erythema nodosum or granulomas), polyarthralgia/arthritis, respiratory symptoms (cough, dyspnea), fever, uveitis, hepatosplenomegaly, parotid enlargement, upper respiratory tract involvement, neurologic symptoms.

Reprinted with permission from Mañá J, et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med 1999;107:241.

Information about the season of onset, radiographic results, clinical course and laboratory test results was collected on all patients diagnosed with Löfgren's syndrome. The blood work included determination of angiotensin-converting enzyme levels. Treatment during the study was not directed; most of the patients received nonsteroidal anti-inflammatory agents or potassium iodide. A total of 186 patients was included in the study. Most of the patients were white women, and the mean age was 37 (± 11) years. The onset of symptoms in nearly one half of the patients was between April and June. Almost all (93 percent) of the patients had erythema nodosum or periarticular ankle inflammation as their presenting problem; these were often accompanied by arthralgia and low-grade fever. Most of the baseline chest radiographs (81 percent) showed hilar or paratracheal adenopathy; none had parenchymal involvement at the time of presentation. One half of the patients had elevated angiotensin-converting enzyme levels, and all of the patients who had gallium-67 scans showed evidence of hilar or right paratracheal uptake. The disease had become inactive in 92 percent of the patients within two years of diagnosis (usually between three and 12 months). Only 6 percent of the patients had recurrent disease between two and 20 years after diagnosis.

The patients with increased levels of angiotensin-converting enzyme were more likely to have persistent or recurrent disease. Most (96 percent) of those with normal levels did not have persistent or recurrent disease. The authors conclude that certain tests should be performed. Specifically, patients who present with periarticular ankle inflammation should have a chest radiograph to look for hilar lymphadenopathy. Patients, whether asymptomatic or with erythema nodosum or uveitis, may have a diagnosis of sarcoidosis supported by a finding of bilateral lymphadenopathy along with an elevated angiotensin-converting enzyme level plus a negative tuberculin test. If the chest radiograph is not helpful, a typical pattern on gallium-67 scan may prove highly suggestive. Routine biopsy is not needed to confirm the diagnosis but may be needed in patients whose presentation is atypical.

Lymphoma, tuberculosis or malignancy must be excluded in the face of a chest radiograph that does not show symmetric bilateral lymphadenopathy. Patients should be reassured that Löfgren's syndrome is benign and usually self-limited. Follow-up should continue until hilar adenopathy has resolved.

Mañá J, et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med. September 1999;107:240–5.



Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article